Keio University · 의학
Shigeaki Suzuki 교수의 연구실은 신경염증 및 자가면역성 근병증, 특히 인지질성 근염증(myositis)과 관련된 자가항체(예: anti-SRP, anti-HMGCR, anti-OJ)의 진단적 및 병태생리적 역할을 중심으로 연구를 진행하고 있습니다. 특히 면역관문 억제제 투여 후 발생하는 근병증(MG)의 조기 진단과 IL-6와 같은 신경세포유지 인자들이 뇌경색 이후 뇌 손상과 복구 과정에서 수행하는 이중적 역할에 대한 기초 연구도 수행하고 있습니다. 이들의 연구는 신경면역학적 질환의 메커니즘 규명과 치료 전략 개발에 기여하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The prompt and correct recognition of MG following treatment with immune checkpoint inhibitors in patients with cancer is important.
Anti-SRP antibodies are associated with severe neurological symptoms, more so than are anti-HMGCR antibodies. Although these autoantibodies are independent serological markers associated with IMNM, patients bearing either share common characteristics.
Interleukin-6 (IL-6) is pleiotropic cytokine involved in many central nervous system disorders including stroke, and elevated serum IL-6 has been found in acute stroke patients. IL-6 is implicated in the inflammation, which contributes to both injury and repair process after cerebral ischemia. However, IL-6 is one of the neurotrophic cytokines sharing a common receptor subunit, gp130, with other neurotrophic cytokines, such as leukemia inhibitory factor (LIF) and ciliary neurotrophic factor. The
Anti-SRP antibodies are associated with different clinical courses and histological presentations.
Although clinical presentations of antisynthetase syndrome were relatively homogeneous, anti-OJ antibodies were associated with severe muscle involvement. Antisynthetase syndrome is a clinical and histological subset among idiopathic inflammatory myopathies.
Although interleukin-6 (IL-6) has various neuroprotective effects against cerebral ischemia, the topographic distribution and cellular source of IL-6 after cerebral ischemia remain unclear. In the current study, the localization of IL-6 protein was immunohistochemically examined in rats after 3.5, 12, 24, and 48 hours of reperfusion after 1.5 hours of middle cerebral artery occlusion. Middle cerebral artery occlusion was induced by the intraluminal suture method. The specificity of the anti-IL-6
A subset of patients with anti-SRP myopathy can show a chronic progressive form associated with severe clinical deficits.
Myasthenia gravis (MG) is caused by antibodies that react mainly with the acetylcholine receptor on the postsynaptic site of the neuromuscular junction. A wide range of clinical presentations and associated features allow MG to be classified into subtypes based on autoantibody status. Striational antibodies, which react with epitopes on the muscle proteins titin, ryanodine receptor (RyR), and Kv1.4, are frequently found in MG patients with late-onset and thymoma. Antititin and anti-RyR antibodie
It has been demonstrated that anti-Kv1.4 antibodies are possible markers for cardiac involvements in MG patients.
Statins have a variety of myotoxic effects and can trigger the development of inflammatory myopathies or myasthenia gravis (MG) mediated by immunomodulatory properties. Autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) have been identified in patients with statin-associated myopathy. The purpose of the present study is to develop an enzyme-linked immunosorbent assay (ELISA) of anti-HMGCR antibodies and to elucidate the clinical significance of anti-HMGCR antibodies in Jap
Anti-SRP antibody is useful for discriminating PM from MD among patients with myopathies.
